All In Biotech

Drug Trial Radar · NCT06845241

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Feb 2025

Primary completion

Jul 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.

Conditions

  • Relapsed or Refractory Non-Hodgkin Lymphoma

Interventions

  • ICP-490Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0Time frame: Through study completion,an average of 3 years
  2. Incidence, type, and severity of dose-limiting toxicities (DLTs);Time frame: Through study completion,an average of 3 years
  3. Recommended Phase 2 Doses(RP2Ds) and/or maximum tolerated doses(MTDs).Time frame: Through study completion,an average of 3 years
  4. ORR assessed according to the Lugano criteria (Cheson 2014).Time frame: Through study completion,an average of 3 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Henan Cancer Hosptital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.